Innovent Biologics Inc
01801: XHKG (HKG)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
HKD 47.60 | Gdts | Vlbvvhycj |
Innovent’s Full-Year Results in Line; FVE Unchanged; Remains our Top Pick
Narrow-moat Innovent’s results were in line with our expectations. Revenue was CNY 4.3 billion, or 11% year-on-year growth. Our fair value estimate is HKD 50.00 per share, and Innovent is our top pick in Chinese healthcare companies right now.